Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal International Journal of Cell and Biomedical Science
Jutadi
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
hUC-MSCs Therapy with EVs Booster Improves Recovery in Stage 2 Chronic Kidney Disease with Hypercholesterolemia : a case report Jutadi; Ayu, Dian Respati; Cahyani, Dini; Arda, Adzani Gaisani; Anggoro, Naufal Sebastian
International Journal of Cell and Biomedical Science Vol 3 No 9 (2024)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v3i9.63

Abstract

Hypercholesterolemia is a common metabolic comorbidity that accelerates the progression of chronic kidney disease (CKD). Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and their secretome, which consist of extracellular vecicles (EVs) and soluble bioactive molecules, have shown potential in modulating inflammation and metabolism. This case report describes significant improvement in serum lipid profile following hUC-MSC and secretome therapy in a patient with stage 2 CKD and hypercholesterolemia. A male patient with CKD stage 2 received two intravenous cycles of hUC-MSC and secretome therapy administered seven months apart. Serial evaluations demonstrated a progressive decline in total cholesterol from 294 mg/dL at baseline to 286 mg/dL after the first treatment and 225 mg/dL after the second. LDL cholesterol decreased from 188 mg/dL to 140 mg/dL, with a mild rebound to 175 mg/dL. HDL cholesterol, initially elevated at 214 mg/dL, showed a modest increase to 220 mg/dL after the first treatment, followed by normalization to 175 mg/dL. Triglyceride levels remained within the normal range (44–51 mg/dL) throughout the observation period. The marked improvement in lipid parameters suggests that hUC-MSC and secretome therapy may exert systemic metabolic regulation via anti-inflammatory, antioxidative, and hepatoprotective mechanisms. hUC-MSC and secretome administration demonstrated potential benefits in lipid homeostasis in a patient with CKD and hypercholesterolemia. These findings support the role of MSC-derived secretome as a promising adjunctive therapeutic approach. Larger controlled trials are warranted to confirm these outcomes and elucidate underlying mechanisms.
Human-Umbilical Cord-Mesenchymal Stem Cells (hUC-MCSs) Therapy with Extravesicles (EVs) Booster Improves Recovery in Type 2 Diabetes Mellitus with Cardiovascular Disease Nugraha, Dendi Krisna; Jutadi; Anggoro, Naufal Sebastian; Sari, Fikriya Novita; Ardani, Yanuar
International Journal of Cell and Biomedical Science Vol 4 No 10 (2025)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v4i10.66

Abstract

Background: Type 2 diabetes (T2DM) is a chronic metabolic disorder characterized by insulin resistance and β-cell dysfunction, leading to persistent hyperglycemia and complications. Studies have explored mesenchymal stem cell (MSC)-based therapies and their extracellular vesicles (EVs) as novel approaches for metabolic regulation and tissue repair. Case: A 43-year-old male patient exhibited symptoms including excessive thirst and hunger, frequent urination, fatigue, and intermittent blurry vision. He had type 2 diabetes and recently worsened symptoms. The obese patient had elevated blood glucose, HbA1c, triglycerides, and uric acid. He received umbilical cord-derived mesenchymal stem cells (161,6 × 106 cells), followed by seven intramuscular EV injections (1.5 cc each), along with diet and antioxidant supplements. Results: Three months after the conclusion of treatment, laboratory test showed significant improvement, with fasting glucose levels measuring at 91 mg/dL, HbA1c levels at 5,1%, triglyceride levels at 151 mg/dL, uric acid levels at 4,9 mg/dL, and an erythrocyte sedimentation rate of 12 mm/hr. The clinical symptoms such as nocturia, fatigue, and neuropathic pain, demonstrated a substantial improvement, as well as led to the resolution of skin xerosis and heel fissures. Conclusion: This case suggests that combined UC-MSC and EV therapy, complemented by lifestyle modification, may contribute to metabolic stabilization and symptomatic relief in T2DM patients.
Co-Authors Anggoro, Naufal Sebastian Arda, Adzani Gaisani Ardani, Yanuar Ayu, Dian Respati Cahyani, Dini Nugraha, Dendi Krisna Sari, Fikriya Novita